London Daily

Focus on the big picture.
Friday, Aug 22, 2025

Weight loss drug semaglutide approved for NHS use

Weight loss drug semaglutide approved for NHS use

A weight loss jab that has gained popularity in the US has been approved for use by the NHS in England.

The National Institute for Health and Care Excellence (NICE) concluded semaglutide, marketed as Wegovy, is safe, effective and affordable.

Delivered via an injection into the skin, the drug makes people feel fuller and more satisfied, so they eat less.

Famous personalities such as Elon Musk claim to have used it - with a "craze" allegedly developing in Hollywood.


Lifestyle changes


Based on evidence from clinical trials, NICE says semaglutide could help people reduce their weight by over 10%, if implemented alongside nutrition and lifestyle changes.

It will be recommended for use by people with at least one weight-related health condition, as well as those who have a body mass index (BMI) which puts them near the top of the obese range.

BMI is calculated by dividing an adult's weight in kilograms by the square of their height in metres.

Those who are lower on the obese BMI range - a BMI between 30 and 34.9kg/m2 - could also be offered the drug if they have a weight-related health condition. NICE lists these as someone who is pre-diabetic, has type 2 diabetes, high blood pressure, heart disease or obstructive sleep apnoea.

Once-weekly injections of Wegovy will have to be prescribed by a specialist, and an individual will only be able to take the drug for a maximum of two years.

Semaglutide is also found in the diabetes medicine Ozempic, but, unlike Ozempic - which is intended for those with type 2 diabetes - Wegovy is recommended specifically for weight loss.

The drug works as an appetite suppressant by mimicking a hormone called Glucagon-like peptide-1 (GLP-1). This intestinal hormone is released after eating and typically makes people feel fuller, so should help reduce overall calorie intake.

Kailey Wood runs a TikTok account sharing her weight loss journey


An article published last year in Variety suggested the diabetes medicine Ozempic, which contains semaglutide, is being used by some professionals in the film and entertainment industry to lose weight quickly.

It has become so popular that there are currently widespread shortages in the US and concerns for those people who rely on the drug for medical reasons.

Insurance companies in the US are refusing to cover its use among people who are not diabetic and not taking it as a prescribed medicine.


'Ozempic face'


Pharmaceutical company Novo Nordisk, which makes both Ozempic and Wegovy, says the products should only be used as recommended by a doctor.

Like all medication, semaglutide comes with side-effects and risks - including nausea, stomach pain, vomiting and diarrhoea.

In addition, rapid weight loss can also lead to the skin losing collagen and elastin, causing what Vogue Magazine has dubbed the gaunt "Ozempic face".

Kailey Wood, 36, has been taking Ozempic for seven months, after being prescribed the drug by her doctor in New York.

She tells the BBC that she has lost just under 30kg - going from obese to healthy in the BMI range.

Semaglutide injections will be approved under NICE guidance


"I have Polycystic Ovarian Syndrome (PCOS) and insulin resistance, but honestly I didn't really struggle with my weight until I hit my 30s - after I had my kids," she says.

"I was rapidly gaining weight. I had a personal trainer and was on every diet known to man - keto, low carbohydrate, intermittent fasting and nothing seemed to work,".

When Kailey went for tests with her doctor, she was told she had high blood pressure and high cholesterol and, due to the risks associated with PCOS, she was at risk of developing type 2 diabetes too.

"The long-term effects [of being obese] freaked me out having two daughters," she says.

"I just wanted to get to my best self - to show them what a healthy mum looks like; to get outside and play with them."

Kailey, who works for a tech start-up and runs her own TikTok page, says that people who want to use semaglutide need to know the drug does have side-effects.

"When you start taking this medication, your body almost goes into shock - you get headaches, nausea, tiredness," she explains.

"But your body starts to get used to it. You have to be mindful and listen to your body."

Kailey says those elements of the US media who promoting the drug as a "get skinny quick product" leave "a bad taste". She believes it sends the wrong message.

"What it's really doing is changing people's lives - treating the patient before they have the disease," she says.

Just over a quarter of adults in England are obese and around a third are overweight, according to official figures.

In the UK, obesity is thought to cost the NHS £6.1bn per year, government estimates show.

The drug semaglutide is currently under consultation in Scotland, with Wales expected to follow the NICE guidelines issued in England.

Helen Knight, director of medicines evaluation at NICE, said: "For some people losing weight is a real challenge, which is why a medicine like semaglutide is a welcome option.

"It won't be available to everyone. Our committee has made specific recommendations to ensure it remains value for money for the taxpayer."

Dr Duane Mellor, registered dietitian and senior lecturer at Aston Medical School, Aston University, said: "It is important to remember that living with a higher body weight or obesity is not a lifestyle choice, and people wanting to improve their health should be supported to do that.

"It is also clear that semaglutide is not intended to be a lifestyle weight-loss product in the UK. It is to be used for the purpose of improving health."

Anyone who is offered semaglutide on the NHS will be supported by specialist weight management services, including support from a dietitian.

Newsletter

Related Articles

0:00
0:00
Close
After 200,000 Orders in 2 Minutes: Xiaomi Accelerates Marketing in Europe
Ukraine Declares De Facto War on Hungary and Slovakia with Terror Drone Strikes on Their Gas Lifeline
Animated K-pop Musical ‘KPop Demon Hunters’ Becomes Netflix’s Most-Watched Original Animated Film
New York Appeals Court Voids Nearly $500 Million Civil Fraud Penalty Against Trump While Upholding Fraud Liability
Elon Musk tweeted, “Europe is dying”
Far-Right Activist Convicted of Incitement Changes Gender and Demands: "Send Me to a Women’s Prison" | The Storm in Germany
Hungary Criticizes Ukraine: "Violating Our Sovereignty"
Will this be the first country to return to negative interest rates?
Child-free hotels spark controversy
North Korea is where this 95-year-old wants to die. South Korea won’t let him go. Is this our ally or a human rights enemy?
Hong Kong Launches Regulatory Regime and Trials for HKD-Backed Stablecoins
China rehearses September 3 Victory Day parade as imagery points to ‘loyal wingman’ FH-97 family presence
Trump Called Viktor Orbán: "Why Are You Using the Veto"
Horror in the Skies: Plane Engine Exploded, Passengers Sent Farewell Messages
MSNBC Rebrands as MS NOW Amid Comcast’s Cable Spin-Off
AI in Policing: Draft One Helps Speed Up Reports but Raises Legal and Ethical Concerns
Shame in Norway: Crown Princess’s Son Accused of Four Rapes
Apple Begins Simultaneous iPhone 17 Production in India and China
A Robot to Give Birth: The Chinese Announcement That Shakes the World
Finnish MP Dies by Suicide in Parliament Building
Outrage in the Tennis World After Jannik Sinner’s Withdrawal Storm
William and Kate Are Moving House – and the New Neighbors Were Evicted
Class Action Lawsuit Against Volkswagen: Steering Wheel Switches Cause Accidents
Taylor Swift on the Way to the Super Bowl? All the Clues Stirring Up Fans
Dogfights in the Skies: Airbus on Track to Overtake Boeing and Claim Aviation Supremacy
Tim Cook Promises an AI Revolution at Apple: "One of the Most Significant Technologies of Our Generation"
Apple Expands Social Media Presence in China With RedNote Account Ahead of iPhone 17 Launch
Are AI Data Centres the Infrastructure of the Future or the Next Crisis?
Cambridge Dictionary Adds 'Skibidi,' 'Delulu,' and 'Tradwife' Amid Surge of Online Slang
Bill Barr Testifies No Evidence Implicated Trump in Epstein Case; DOJ Set to Release Records
Zelenskyy Returns to White House Flanked by European Allies as Trump Pressures Land-Swap Deal with Putin
The CEO Who Replaced 80% of Employees for the AI Revolution: "I Would Do It Again"
Emails Worth Billions: How Airlines Generate Huge Profits
Character.ai Bets on Future of AI Companionship
China Ramps Up Tax Crackdown on Overseas Investments
Japanese Office Furniture Maker Expands into Bomb Shelter Market
Intel Shares Surge on Possible U.S. Government Investment
Hurricane Erin Threatens U.S. East Coast with Dangerous Surf
EU Blocks Trade Statement Over Digital Rule Dispute
EU Sends Record Aid as Spain Battles Wildfires
JPMorgan Plans New Canary Wharf Tower
Zelenskyy and his allies say they will press Trump on security guarantees
Beijing is moving into gold and other assets, diversifying away from the dollar
Escalating Clashes in Serbia as Anti-Government Protests Spread Nationwide
The Drought in Britain and the Strange Request from the Government to Delete Old Emails
Category 5 Hurricane in the Caribbean: 'Catastrophic Storm' with Winds of 255 km/h
"No, Thanks": The Mathematical Genius Who Turned Down 1.5 Billion Dollars from Zuckerberg
The surprising hero, the ugly incident, and the criticism despite victory: "Liverpool’s defense exposed in full"
Digital Humans Move Beyond Sci-Fi: From Virtual DJs to AI Customer Agents
YouTube will start using AI to guess your age. If it’s wrong, you’ll have to prove it
×